CR and, in particular, insulin/IGF1 inhibition slows down the cell cycle and thus global tumor growth, but at the same time attenuates responsiveness to innate immune pathways that would induce cancer stem-cell clearance, favoring their persistence. This evidence concerns the gene INS and cancer.